• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide

    3/29/22 2:49:13 PM ET
    $AVAH
    $IGMS
    $LOVE
    $MKC
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVAH alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday.

    The Dow traded up 0.73% to 35,209.63 while the NASDAQ rose 1.67% to 14,595.34. The S&P also rose, gaining, 1.01% to 4,621.59.

    Also check this: Alphabet And 3 Other Stocks Sold By Insiders


    Leading and Lagging Sectors


    Real estate shares jumped by 2.6% on Monday. Meanwhile, top gainers in the sector included Power REIT (NYSE:PW), up 16% and Opendoor Technologies Inc. (NASDAQ:OPEN) up 12%.


    In trading on Monday, energy shares fell 1.1%.


    Top Headline


    McCormick & Co Inc (NYSE:MKC) reported better-than-expected earnings for its first quarter.


    McCormick reported first-quarter FY22 sales growth of 2.7% year-on-year, to $1.52 billion, beating the consensus of $1.47 billion. Adjusted EPS of $0.63 beat the consensus of $0.62.


    McCormick reiterated its FY22 sales, operating income, and EPS outlook. The company sees FY22 sales growth of 3% - 5% Y/Y. It expects FY22 Adjusted EPS of $3.17 - $3.22, against the consensus of $3.19.

     

    Equities Trading UP


    IGM Biosciences, Inc. (NASDAQ:IGMS) shares shot up 93% to $28.89. Sanofi SA (NASDAQ:SNY) and IGM Biosciences signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immunology/inflammation targets.


    Shares of Randolph Bancorp, Inc. (NASDAQ:RNDB) got a boost, shooting 26% to $26.49 after Hometown Financial Group announced plans to acquire Randolph Bancorp for $27 per share in cash.


    The Lovesac Company (NASDAQ:LOVE) shares were also up, gaining 16% to $54.59. Lovesac reported fourth-quarter FY22 sales growth of 51.3% year-on-year, to $196.2 million, beating the consensus of $174.33 million.


    Equities Trading DOWN

    NeoGenomics, Inc. (NASDAQ:NEO) shares tumbled 26% to $13.12 after the company announced it expects Q1 sales to be below its previously issued guidance range and withdrew its FY22 guidance. The company also announced Mark Mallon has agreed to step down as CEO.


    Shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) were down 27% to $3.92 after the company said FY21 EPS results were down from last year. The company also issued FY22 sales guidance below analyst estimates. B of A Securities downgraded the stock from Buy to Neutral and lowered the price target from $10 to $5.5.


    Progenity, Inc. (NASDAQ:PROG) was down, falling 24% to $1.23 after the company reported Q4 earnings results.

    Also check out: Executives Buy More Than $12M Of 3 Stocks


    Commodities

    In commodity news, oil traded down 1.2% to $104.71, while gold traded down 1.2% to $1,916.70.


    Silver traded down 1.2% Tuesday to $24.90 while copper rose 0.3% to $4.7405.



    Euro zone

    European shares closed higher today. The eurozone’s STOXX 600 gained 1.74%, London’s FTSE 100 rose 0.86%, while Spain’s IBEX 35 Index rose 2.98%. The German DAX gained 2.79%, French CAC 40 climbed 3.08% and Italy’s FTSE MIB Index rose 2.41%.

    Consumer credit in the UK rose by GBP 1.9 billion in February. Retail sales in Spain rose 0.9% year-over-year in February, while consumer confidence in France declined to 91 in March from 97 in February. Import prices in Germany rose 26.3% year-over-year in February, while GfK Consumer Climate Indicator declined to -15.5 heading to April.

     

    Economics

     

    The S&P CoreLogic Case-Shiller home price index increased 19.1% in January.


    The FHFA house price index rose 1.6% from a month ago in January.


    The Conference Board’s consumer confidence index rose to 107.20 in March, versus a revised level of 105.70.


    Check out this: Walmart And 3 Other Stocks Sold By Insiders

    Check out our premarket coverage here .


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 81,658,970 cases with around 1,004,240 deaths. India confirmed a total of at least 43,021,980 cases and 521,090 deaths, while Brazil reported over 29,852,340 COVID-19 cases with 659,010 deaths. In total, there were at least 483,970,220 cases of COVID-19 worldwide with more than 6,153,200 deaths.

    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH
    $IGMS
    $LOVE
    $MKC

    CompanyDatePrice TargetRatingAnalyst
    Sanofi
    $SNY
    2/12/2026Buy → Neutral
    BofA Securities
    Sanofi
    $SNY
    1/27/2026Neutral
    Citigroup
    Sanofi
    $SNY
    1/16/2026Buy → Neutral
    UBS
    Sanofi
    $SNY
    1/6/2026Overweight → Equal Weight
    Barclays
    McCormick & Company Incorporated
    $MKC
    12/15/2025$75.00Hold → Buy
    Deutsche Bank
    Sanofi
    $SNY
    12/9/2025Buy → Neutral
    Guggenheim
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Sanofi
    $SNY
    12/8/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi downgraded by BofA Securities

    BofA Securities downgraded Sanofi from Buy to Neutral

    2/12/26 7:23:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by UBS

    UBS downgraded Sanofi from Buy to Neutral

    1/16/26 8:32:26 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q4 2025 Open House: Opendoor 2.0 Does What It Said It Would Do — Delivering Acquisition Growth, Faster Inventory Turns, and Stronger Cohorts

    SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN), a leading e-commerce platform for residential real estate transactions, today reported financial results for its fourth quarter and year ended December 31, 2025. "Last quarter, we outlined a four-step plan to transform Opendoor: reach breakeven Adjusted Net Income by the end of 2026 on a 12-month go-forward basis, drive positive unit economics while increasing transaction velocity, transition to direct-to-consumer relationships, and expand our product suite. This quarter demonstrates we are executing on that plan," said Kaz Nejatian, CEO of Opendoor. "These results reflect structural improvements in

    2/19/26 4:05:00 PM ET
    $OPEN
    Real Estate
    Finance

    NeoGenomics to Participate in Upcoming Investor Conferences

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 3, at 1:10 pm ET, accessible here Leerink Global Healthcare Conference in Miami, FL Fireside chat on Tuesday, March 10, at 4:20 pm ET, accessible here Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer geneti

    2/18/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Shaner Jeff sold $3,411,399 worth of shares (461,909 units at $7.39), decreasing direct ownership by 15% to 2,650,892 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:16:05 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Chief Compliance Officer Cunningham Patrick A. sold $363,068 worth of shares (49,160 units at $7.39), decreasing direct ownership by 13% to 337,755 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:15:41 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Buckhalter Matthew sold $266,097 worth of shares (36,030 units at $7.39), decreasing direct ownership by 6% to 529,243 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:15:23 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Posner Henry Iii bought $162,929 worth of 7.75% Series A Cum. Red. Perpetual Preferred Stock (24,633 units at $6.61), increasing direct ownership by 263% to 34,000 units (SEC Form 4)

    4 - Power REIT (0001532619) (Issuer)

    2/10/26 2:53:54 PM ET
    $PW
    Real Estate Investment Trusts
    Real Estate

    Amendment: Large owner Posner Henry Iii bought $35,025 worth of 7.75% Series A Cum. Red. Perpetual Preferred Stock (4,797 units at $7.30) (SEC Form 4)

    4/A - Power REIT (0001532619) (Issuer)

    2/10/26 2:00:47 PM ET
    $PW
    Real Estate Investment Trusts
    Real Estate

    Large owner Posner Henry Iii bought $16,120 worth of 7.75% Series A Cum. Red. Perpetual Preferred Stock (2,022 units at $7.97), increasing direct ownership by 28% to 9,367 units (SEC Form 4)

    4 - Power REIT (0001532619) (Issuer)

    2/4/26 6:09:33 PM ET
    $PW
    Real Estate Investment Trusts
    Real Estate

    $AVAH
    $IGMS
    $LOVE
    $MKC
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    2/23/26 9:19:13 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by McCormick & Company Incorporated

    S-3ASR - MCCORMICK & CO INC (0000063754) (Filer)

    2/20/26 4:45:49 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    2/20/26 4:45:31 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    McCormick Appoints Gavin Hattersley and Rick Dierker to Board of Directors

    HUNT VALLEY, Md., Jan. 21, 2026 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today announced that Gavin Hattersley, retired President and Chief Executive Officer of Molson Coors Beverage Company, and Rick Dierker, President and Chief Executive Officer of Church & Dwight Co., Inc., have been appointed to McCormick's Board of Directors effective February 1, 2026. Mr. Hattersley brings more than 35 years of leadership experience spanning the global consumer packaged goods and beverage industries. Most recently, he served as President an

    1/21/26 4:15:00 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Financials

    Live finance-specific insights

    View All

    Q4 2025 Open House: Opendoor 2.0 Does What It Said It Would Do — Delivering Acquisition Growth, Faster Inventory Turns, and Stronger Cohorts

    SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN), a leading e-commerce platform for residential real estate transactions, today reported financial results for its fourth quarter and year ended December 31, 2025. "Last quarter, we outlined a four-step plan to transform Opendoor: reach breakeven Adjusted Net Income by the end of 2026 on a 12-month go-forward basis, drive positive unit economics while increasing transaction velocity, transition to direct-to-consumer relationships, and expand our product suite. This quarter demonstrates we are executing on that plan," said Kaz Nejatian, CEO of Opendoor. "These results reflect structural improvements in

    2/19/26 4:05:00 PM ET
    $OPEN
    Real Estate
    Finance

    NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

    Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights   Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37

    2/17/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    Opendoor 4Q25 Financial Open House: Opendoor to Report Fourth Quarter and Full Year 2025 Financial Results on February 19th, 2026

    SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor") (NASDAQ:OPEN) today announced that it will report fourth quarter and full year 2025 financial results for the period ended December 31, 2025 following the close of the market on Thursday, February 19, 2026. Modernizing Investor AccessOn February 19, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company's business and financial results. We believe in building in the open. The Financial Open House replaces the traditional earnings conference call with a video event, including a live segment for shareholder Q&A. Shareholder Q&AWe invi

    1/30/26 9:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    $AVAH
    $IGMS
    $LOVE
    $MKC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Power REIT (MD)

    SC 13D/A - Power REIT (0001532619) (Subject)

    12/10/24 5:55:44 PM ET
    $PW
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by The Lovesac Company

    SC 13G/A - Lovesac Co (0001701758) (Subject)

    11/14/24 4:34:24 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care